Overview

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

Status:
Not yet recruiting

Trial end date:
2026-04-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Loxo Oncology, Inc.